Searchable abstracts of presentations at key conferences in endocrinology

ea0081d1.1 | PRRT or targeted molecular therapies as preferred line of treatment | ECE2022

For: PRRT or targeted molecular therapies as preferred line of treatment

de Herder Wouter W

Purpose: Bronchopulmonary (BP) and gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with 177Lutetium-labeled somatostatin analogues.Experimental Design: Patients receive four treatments of 177Lu-DOTATATE at a dose of 7.4 GBq every 8 weeksResults: An objective resp...

ea0016me14 | (1) | ECE2008

Management of GI-NET

de Herder Wouter W

According to the WHO classification system the majority of endocrine tumours of the gastrointestinal tract (GI-NETs) are considered as being well differentiated benign or malignant tumours. Almost all GI-NETs are derived from enterochromaffin or Kulchitsky cells that can synthesize, store and secrete serotonin. The majority of these tumours are non-functioning and their presentation is non-specific. Functioning tumours, may exhibit protean clinical presentation, depending on t...

ea0081rc6.2 | Rapid Communications 6: Endocrine-Related Cancer | ECE2022

Reciprocal interactions between fibroblast and pancreatic neuroendocrine tumor cells: putative impact of the tumor microenvironment

Cuny Thomas , Mondielli Gregoire , van Koetsveld Peter , de Herder Wouter , Barlier Anne , Hofland Leo

Introduction: Pancreatic neuroendocrine neoplasms (PNEN) present with a fibrotic stroma which constitutes the tumor microenvironment (TME). The role played by stromal fibroblasts over the growth of PNEN and their sensitivity to the mTOR inhibitor, RAD001, are as yet unestablished.Methods: We investigated reciprocal interactions between 1) human PNEN cell lines (BON-1/QGP-1) or primary cultures of human ileal neuroendocrine neoplasm (iNEN) or PNEN, and 2)...

ea0041ep994 | Thyroid (non-cancer) | ECE2016

Sorafenib-induced changes in thyroid hormone levels in patients with hepatocellular carcinoma

Beukhof Carolien , Bins Sander , van Doorn Leni , de Herder Wouter , Visser Theo , Mathijssen Ron , Peeters Robin

Background: Recent studies suggest enhanced peripheral thyroid hormone metabolism as an explanation for the changes in thyroid hormone levels in patient treated with Sorafenib.Methods: In this single centre, prospective, observational cohort study 60 patients with hepatocellular carcinoma were treated with Sorafenib. Thyroid stimulating hormone (TSH) and free thyroxine (FT4) were measured at baseline (time-0), at 6 weeks (time-1) and at the end of therap...

ea0037ep37 | Adrenal cortex | ECE2015

Pregnancy-induced Cushing's syndrome

Andreescu Corina , Hofland Leo , Hofland Hans , Looijenga Leendert , de Herder Wouter , Feelders Richard

Cushing’s syndrome (CS) during pregnancy is a rare metabolic condition with only a few cases reported in the literature. Misdiagnosis of CS is common because of the overlapping features of fatigue, weight gain, striae, and emotional changes that occur during normal pregnancy. The clinical presentation together with laboratory and imaging findings help to make a diagnosis. However, changes in maternal hormones and their binding proteins complicate assessment of the normal ...

ea0020p556 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Combined treatment for acromegaly with long-acting somatostatin analogues and pegvisomant: long-term safety up to 4.5 years of follow-up in 86 patients

Neggers Sebastian , De Herder Wouter , Janssen Joop , Feelders Richard , Van Der Lely Aart-Jan

Background: We previously reported on the efficacy, safety and Quality of Life of long-acting somatostatin analogs (SSA) and (twice) weekly pegvisomant (PEG-V) in acromegaly and improvement after the addition of PEG-V to long-acting SSA.Objective: To assess the long term safety in a larger group of acromegalic patients over a larger period of time; 29.2 (1.2–57.4) months (mean (range)).Design: Pegvisomant was added to SSA mono...

ea0081p411 | Pituitary and Neuroendocrinology | ECE2022

Independent injection vs healthcare-setting administration of somatostatin analogues: A systematic literature review

Luiz Boguszewski Cesar , Korbonits Marta , Artignan Audrey , Martin Garcia Almudena , Houchard Aude , Ribeiro-Oliveira Antonio , W de Herder Wouter

Background: A systematic literature review (SLR) was conducted to assess the use of independent injections (self/partner/home-administered) as an alternative to healthcare-setting injections for chronic diseases. The primary objective was to identify studies reporting on independent injection of somatostatin analogues (SSAs). Comparative evidence on independent injection of other medications was examined as a secondary objective.Methods: MEDLINE/Embase/t...

ea0022p41 | Adrenal | ECE2010

Response of human adrenocortical carcinoma to mitotane treatment in vitro

van Koetssveld Peter , van Rutte Karlijn , Waaijers Marlijn , de Krijger Ronald , Lamberts Steven , Feelders Richard , de Herder Wouter , Hofland Leo

Introduction: Adrenocortical carcinoma (ACC) is a rare, but highly malignant endocrine tumor. Surgery is the primary choice of treatment. In case of inoperable disease or tumor recurrence, therapy with the adrenolytic drug mitotane is usually applied. Plasma mitotane concentrations of >14 mg/l (50 μM) seem required for an effect on tumor mass. Despite its clinical use, the effects of mitotane on cell proliferation and hormone production have been poorly investigated <...

ea0020p551 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

The low-dose ACTH stimulation test in the assessment of outcome of pituitary surgery for Cushing's disease

Alwani Rehmat A , De Herder Wouter W , De Jong Frank H , Van der Lely Aart-Jan , Feelders Richard A

Objective: To evaluate the results of the early postoperative low-dose (1 μg) ACTH (adrenocorticotropin) stimulation test in patients with Cushing’s disease (CD) in order to predict long-term outcome of transsphenoidal surgery.Methods: We reviewed the serum cortisol response to 1 μg synthetic ACTH (1–24) in the second week after pituitary surgery in 40 patients with Cushing’s disease. Median follow-up was 48.5 months (range 6&#15...

ea0016p115 | Clinical cases | ECE2008

The influence of application site on testosterone serum concentrations after transdermal testosterone gel

Neggers Sebastian , Feelders Richard , van Aken Maarten , de Herder Wouter , van der Lely Aart-Jan , de Jong Frank

Background: Testosterone (T) in a hydroalcoholic gel is commonly prescribed as androgen replacement therapy and may not be accompanied by peaks and troughs of serum T levels as seen in T-injectables. We assessed in 17 subjects the differences in serum testosterone (sT) and free T (fT) levels during four different application periods.Methods: Patients where on daily 50 mg Androgel®, for 7 consecutive days in each cycle, on day 8 serum was ...